Drug guidance
Sotorasib for previously treated KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer
Condition
Cancer
Respiratory
16 September 2025
-
Published on 16 Sep 2025
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended sotorasib for inclusion on the MOH List of Subsidised Drugs for previously treated Kirsten Rat Sarcoma glycine-to-cysteine at Codon 12 (KRAS G12C)-mutated locally advanced or metastatic non-small-cell lung cancer. The decision was based on lack of clinical- and cost-effectiveness of sotorasib compared with docetaxel, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for sotorasib are provided in the Annex.